The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple-negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2, 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple-negative. Survival was longer with type 1/like CALR, compared to JAK2 (HR 2.6, 95% CI 1.9-3.5), type 2/like CALR (HR 2.5, 95% CI 1.4-4.5), MPL (HR 1.8, 95% CI 1.1-2.9) and triple-negative mutational status (HR 2.4, 95% CI 1.6-3.6), but otherwise similar between the non-type 1/like CALR mutational states (P 5 .41). In multivariable analysis, the absence of type 1/like CALR (P < .001; HR 2, 95% CI 1.4-2.7), presence of ASXL1/SRSF2 mutations (P < .001; HR 1.9, 95% CI 1.5-2.4) and DIPSS-plus (P < .001) were each predictive of inferior survival. Furthermore, among 210 patients with ASXL1/SRSF2 mutations, survival was significantly longer in the presence vs. absence of type 1/like CALR mutations (median 5.8 vs. 2.9 years; P < .001). Triple-negative status did not disclose additional prognostic information for overall or leukemia-free survival. The observations regarding the prognostic distinction between CALR mutation variants were validated in an external cohort of 386 patients from the University of Florence Careggi hospital. We conclude that type 1/like CALR mutations in PMF not only predict superior survival, but also partially amend the detrimental effect of high molecular risk mutations.
| I N TR ODU C TI ON
More than 90% of patients with myeloproliferative neoplasms (MPN) express one of three "driver" mutations, including Janus kinase 2 (JAK2), calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL).
1 JAK2 mutations were first described in 2005 and accompany polycythemia vera (PV) in virtually all cases, but are also present in approximately 60% of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). 2 In 2006, MPL mutations were found to account for the constitutive JAK-STAT activation in 3% to 10% of ET or PMF patients. 3 CALR mutations in MPN were first reported in 2013 and partially addressed the molecular gap in JAK2/MPL mutationnegative ET and PMF, with mutational frequencies ranging between 20% and 25%. 4, 5 In the original reports of their description, 4,5 CALR mutations were associated with higher platelet count, lower risk of thrombosis and better survival in ET and PMF and increased risk of fibrotic transformation in ET. 4, 5 However, not all of the observations on prognostic impact were confirmed in subsequent studies, save for the associations with longer survival in PMF and lower risk of thrombosis in ET. 6, 7 Driver mutational frequencies in World Health Organization (WHO)-defined PMF (JAK2 58%, CALR 25%, MPL 8%, and triplenegative 9%) and ET (JAK2 62-64%, CALR 15-24%, MPL 4% and triple-negative 10-16%) are now well delineated. 6, 8 Furthermore, over 80% of CALR mutations seen in MPN are represented by so-called type 1 or type 2 variants; 9 type 1 constitutes a 52-bp deletion (p.
L367fs*46) and type 2 a 5-bp TTGTC insertion (p.K385fs*47). 4, 5, 9, 10 13 In the current much larger study of 1,095
informative cases, we confirm our earlier observations and provide additional details.
| M E TH ODS
The current study was approved by the institutional review boards of Table 1 provides additional details on presenting clinical and laboratory characteristics of the study patients, stratified by driver mutational status.
| Phenotypic comparisons
As outlined in Table 1 , younger age was associated with CALR mutations, especially type 1/like CALR (P < .01), red cell transfusion need was higher in triple-negative cases and lowest with CALR mutations (P < .01), leukocyte count was higher with type 2/like CALR and JAK2 mutations (P < .01), platelet count was higher with CALR mutations and lowest in triple-negative cases (P < .01), circulating blast count was highest with type 2/like CALR mutations (P < .01), constitutional symptoms were more frequent with JAK2 mutations and in triple-negative cases (P 5 .03), DIPSS-plus risk distribution was lower with type 1/like CALR mutations (P < .01), SRSF2 mutations were infrequent in the presence of CALR mutations (P < .01) and U2AF1 mutations clustered with JAK2 and MPL mutations (P < .01). A similar analysis stratified by the presence or absence of type 1/like CALR mutations disclosed a similar pattern of phenotypic associations (Supporting Information Table 1 ).
| Prognostic comparisons
At a median follow-up of 3.5 years, 475 ( 67%) deaths and 62 ( 9%) leukemic transformations were recorded. In univariate analysis (Table 2 ; These results remained significant or near-significant, during multivariable analysis (Table 2) .
Considering the similar survival data for patients with JAK2 vs.
CALR type 2/like vs. MPL vs. triple-negative mutational states (P 5 .41), 350 (49) 256 (54) 30 (27) 9 (38) 21 (55) 34 (50) <0.0001
Males (%)
457 (64) 301 (64) 71 (63) 16 (67) 24 (63) 45 (66) 0.9
Hemoglobin, g/dL; median (range) 
328 (46) 223 (48) 33 (29) 9 (38) 20 (53) 43 (63) 0.0002
Transfusion -requiring; n (%)
229 (32) 156 (33) 19 (17) 4 (17) 14 (37) 36 (53) <0.0001
Leukocytes, 104 (15) 78 (17) 6 (5) 7 (29) 5 (13) 8 (12) 0.008
Platelets, <0.0001
167 (24) 110 (24) 12 (11) 3 (13) 12 (32) 30 ( 
0.001
Circulating blasts 1%; n (%)
364 (51) 224 (48) 65 (58) 19 (79) 22 (58) 34 (50) 0.02
Constitutional symptoms; n (%)
230 (32) 165 (35) 24 (21) 5 (21) 10 (26) 26 (38) 0.03
<0.0001
High; n (%)
235 (34) 163 (36) 19 (17) 6 (25) 14 (37) 33 (49) Intermediate-2; n (%)
256 (37) 172 (37) 33 (30) 13 (57) 15 (39) 23 (35) Intermediate-1; n (%)
117 (16) 71 (15) 32 (19) 2 (9) 5 (13) 7 (10) Low; n (%) 90 (13) 53 (12) 27 (24) 2 (9) 4 (11) 4 (6) ASXL1-mutated; n (%)
"N" evaluable 5 467
179 (38) 92 (37) 41 (39) 11 (52) 11 (35) 24 (40) 0.7
SRSF2-mutated; n (%)
"N" evaluable 5 466
67 (14) 46 (18) 3 (3) 0 (0) 6 (20) 12 (20) 0.0005
SF3B1-mutated; n (%)
"N" evaluable 5 408
35 (9) 22 (9) 3 (4) 1 (6) 2 (7) 7 (15) 0.3
U2AF1-mutated; n (%)
"N" evaluable 5 448
71 (16) 56 (23) 3 (3) 1 (5) 6 (20) 5 (9) <0.0001 a DIPSS-plus, Dynamic International Prognostic Scoring System-plus uses eight independent predictors of inferior survival: age ASXL1, additional sex combs 1; CALR, calreticulin; JAK2, Janus kinase 2; MPL, MPL proto-oncogene; SF3B1, splicing factor 3B, subunit; SRSF2, serine/arginine-rich splicing factor 2; U2AF1,U2 small nuclear RNA auxiliary factor. *The values in bold indicate a significant P value (<0.05).
and the above-elaborated survival superiority of type 1/like CALR mutations over each one of the nontype 1/like CALR mutational states, we consolidated driver mutational status into "favorable" and "unfavor- Table 1 ). In multivariable analysis, the absence of type 1/like CALR (P < .001; HR 2, 95% CI 1.4-2.7), presence of ASXL1 or SRSF2 mutations (P < .001; HR 1.8, 95% CI Figure 1 ). However, during multivariable analysis, the acute leukemia predictive value of triple-negative mutational status was overshadowed (P value became 0.16) by DIPSS-plus risk and the presence of ASXL1 or SRSF2 mutations ( Table 2) . A similar pattern of significance, in univariate analysis, and nonsignificance, in multivariable analysis, regarding the impact of triple-negative mutational status on leukemia-free survival, was also evident in the Florence patient cohort (Supporting Information Table   3 ). However, in the Florence patient cohort, triple-negative mutational status retained its independent impact on overall survival (Supporting Information ASXL1, additional sex combs 1; CALR, calreticulin; SRSF2, serine/arginine-rich splicing factor 2. *The values in bold indicate a significant P value (<0.05). a DIPSS-plus, Dynamic International Prognostic Scoring System-plus uses eight independent predictors of inferior survival: age >65 years, hemoglobin <10 g/dL, leukocytes >25 3 10 9 /L, circulating blasts 1%, constitutional symptoms, platelet count <100 3 10 9 /L, red cell transfusion dependent and unfavorable karyotype.
| D I SCUSSION
The current study provides strong evidence that supports a two-tiered prognostic classification of driver mutations in PMF, "favorable" and "unfavorable", based on the respective presence or absence of type 1/ like CALR mutations. The favorable prognostic impact of type 1/like CALR mutations was both independent of and complementary to DIPSS-plus and presence or absence of HMR mutations, such as ASXL1 and SRSF2. In this regard, it is important to appreciate the prognostically relevant interaction between driver and HMR mutations, where the presence of type 1/like CALR mutations might have lessened the detrimental effect of HMR mutations. 6 From a practical standpoint, such information might be called upon in order to justify deferral of alloSCT in otherwise DIPSS-plus low or intermediate-1 risk patients harboring HMR mutations. 21 In the current study, among 210 PMF patients with HMR mutations, median survival was 2.9 years in the absence of type 1/like CALR mutations and 5.8 years in its presence.
The prognostic distinction between type 1/like and type 2/like CALR mutations is also supported by their phenotypic differences; in the current study, type 1/like CALR mutated patients, compared to their counterparts with type 2/like CALR mutations, were younger and displayed significantly lower prevalence of marked leukocytosis and circulating blast percentage. Previous studies had suggested that patients with type 2/like CALR mutations were phenotypically more aligned with JAK2-mutated cases. 11, 22 Consistent with this conjecture, in one large study of 939 patients with MPN, the JAK2 46/1 MPN predisposition allele was significantly associated with JAK2 and type 2/ like CALR and not with type 1/like CALR mutations. 23 One notable exception is the risk of thrombosis, which is a characteristic feature of JAK2 and possibly MPL mutations, and not necessarily dependent on the presence or absence CALR mutations. [24] [25] [26] It is possible that structural differences in the novel C-terminal sequences of type 1, type 2 and other CALR mutations are partly responsible for their observed phenotypic and prognostic differences. [27] [28] [29] [30] [31] In one of these studies, type 1, compared to type 2, mutant CALR afforded a greater growth advantage to transduced stem cells and was more potent in inducing thrombocytosis and the fibrotic phenotype in mice. 28 The latter might explain the higher prevalence of type 1 vs. type 2 CALR mutations in PMF vs. ET but is at odds with a previous observation associating type 2/like vs. type 1/like CALR mutations with higher platelet count in ET. 10, 32 Regardless, a biological explanation for the favorable prognostic impact of type 1/like CALR mutations in PMF currently remains elusive.
In contrast to previous suggestions, 6,9 we did not find additional prognostic contribution from triple-negative mutational status, in both some patients harboring novel somatic or germline MPL or JAK2 mutation variants. 33 On the other hand, a recent targeted sequencing study did not reveal significant differences in the spectrum or incidence of other mutations or DNA variants across different driver mutational states. 34 This was also the case in the current study where SRSF2 and ASXL1 mutational frequencies between JAK2 mutated and triplenegative cases. Similarly, the apparent detrimental effect of triplenegative mutational status, on leukemia-free survival, in univariate analysis, appeared to be fully accounted for by its significant association with other risk factors for leukemic transformation, including increased red cell transfusion need and thrombocytopenia. 21, 35 We are fully cognizant of the existence of other studies whose observations regarding the prognostic impact of CALR mutations in PMF are different than ours but we are unable to offer a cogent explanation for the discrepancy. 10, 36 On the other hand, we have recently highlighted the favorable impact of CALR type 1/like mutations in the setting of both prefibrotic and overtly fibrotic PMF. 37, 38 CALR mutations in PMF have also been shown to favorably affect spleen response and survival outcome in the setting of JAK2 inhibitor therapy. 39 Consistent with the observations from the current study, triplenegative mutational status did not affect post-alloSCT outcome in a recent study of patients with primary or secondary myelofibrosis, where CALR mutations were associated with decreased non-relapse mortality and increased overall and progression-free survival; 40 in the particular study, differences in outcome between type 1 and type 2 CALR mutations were not evident. Additional studies in both the transplant and nontransplant settings are needed to confirm the prognostically favorable impact of type 1/like CALR mutations in PMF, in the presence and absence of HMR mutations, and also in post-ET MF, where recent studies have suggested a salutary effect for CALR mutations and a detrimental effect for triple-negative mutational status. 41, 42 
